



March 25, 2022

Perseus Proteomics Inc.
Securities Code: 4882 Mothers TSE

To all stakeholders,

(Amendments) Amendments to “Announcement of Agreement on Termination of License Agreement for PPMX-T004 and License & Knowhow Agreement for PPMX-T002”

Perseus Proteomics Inc. (“the Company”) hereby announces amendments to “Announcement of Agreement on Termination of License Agreement for PPMX-T004 and License & Knowhow Agreement for PPMX-T002” announced today. The revised parts are underlined.

(Before amendment)

“Announcement of Agreement on Termination of License Agreement for PPMX-T004 and License & Knowhow Agreement for PPMX-T002”

Perseus Proteomics Inc. (“the Company”) hereby announces that today its Board of Directors resolved to agree on termination of a license agreement for PPMX-T004 between FUJIFILM Corporation (HQ: Tokyo, Japan/President and CEO, Representative Director: Teiichi Goto, “FUJIFILM”), FUJIFILM Toyama Chemical Co., Ltd. (HQ: Tokyo, Japan/President & COO: Junji Okada, “FF Toyama Chemical”) and the Company as well as a license & knowhow agreement for PPMX-T002 between FUJIFILM and the Company. Both agreements were terminated immediately.

(After amendment)

“Announcement of Agreement on Termination of License Agreement for PPMX-T002 and License & Knowhow Agreement for PPMX-T004”

Perseus Proteomics Inc. (“the Company”) hereby announces that today its Board of Directors resolved to agree on termination of a license agreement for PPMX-T002 between FUJIFILM Corporation (HQ: Tokyo, Japan/ President and CEO, Representative Director: Teiichi Goto, “FUJIFILM”), FUJIFILM Toyama Chemical Co., Ltd. (HQ: Tokyo, Japan/President & COO: Junji Okada, “FF Toyama Chemical”) and the Company as well as a license & knowhow agreement for PPMX-T004 between FUJIFILM and the Company. Both agreements were terminated immediately.

END